Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019

Detalles Bibliográficos
Autores principales: Hartog, Nicholas, Holsworth, Amanda, Rajasekaran, Surender
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642751/
https://www.ncbi.nlm.nih.gov/pubmed/33161152
http://dx.doi.org/10.1016/j.anai.2020.11.005
_version_ 1783606143778553856
author Hartog, Nicholas
Holsworth, Amanda
Rajasekaran, Surender
author_facet Hartog, Nicholas
Holsworth, Amanda
Rajasekaran, Surender
author_sort Hartog, Nicholas
collection PubMed
description
format Online
Article
Text
id pubmed-7642751
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-76427512020-11-05 Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019 Hartog, Nicholas Holsworth, Amanda Rajasekaran, Surender Ann Allergy Asthma Immunol Perspective American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. 2021-02 2020-11-05 /pmc/articles/PMC7642751/ /pubmed/33161152 http://dx.doi.org/10.1016/j.anai.2020.11.005 Text en © 2020 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Perspective
Hartog, Nicholas
Holsworth, Amanda
Rajasekaran, Surender
Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019
title Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019
title_full Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019
title_fullStr Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019
title_full_unstemmed Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019
title_short Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019
title_sort controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642751/
https://www.ncbi.nlm.nih.gov/pubmed/33161152
http://dx.doi.org/10.1016/j.anai.2020.11.005
work_keys_str_mv AT hartognicholas controlledtrialsneededtoproveefficacyandsafetyofconvalescentplasmatherapyincoronavirusdisease2019
AT holsworthamanda controlledtrialsneededtoproveefficacyandsafetyofconvalescentplasmatherapyincoronavirusdisease2019
AT rajasekaransurender controlledtrialsneededtoproveefficacyandsafetyofconvalescentplasmatherapyincoronavirusdisease2019

Ejemplares similares